These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30234574)

  • 1. Advances in Upper Extremity Scleroderma Wound Care.
    Cohen JM; Sibley RA; Chiu ES; Sharma S
    Adv Skin Wound Care; 2018 Oct; 31(10):446-455. PubMed ID: 30234574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonhealing Ulcers in Patients with Tophaceous Gout: A Systematic Review.
    Lam G; Ross FL; Chiu ES
    Adv Skin Wound Care; 2017 May; 30(5):230-237. PubMed ID: 28426572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic sclerosis: Current concepts of skin and systemic manifestations.
    Pearson DR; Werth VP; Pappas-Taffer L
    Clin Dermatol; 2018; 36(4):459-474. PubMed ID: 30047430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous regional anesthesia before surgical peripheral sympathectomy in a patient with severe digital necrosis associated with Raynaud's phenomenon and scleroderma.
    Greengrass RA; Feinglass NG; Murray PM; Trigg SD
    Reg Anesth Pain Med; 2003; 28(4):354-8. PubMed ID: 12945033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scleroderma mimics - Clinical features and management.
    Orteu CH; Ong VH; Denton CP
    Best Pract Res Clin Rheumatol; 2020 Feb; 34(1):101489. PubMed ID: 32147386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raynaud, digital ulcers and calcinosis in scleroderma.
    Nitsche A
    Reumatol Clin; 2012; 8(5):270-7. PubMed ID: 22835924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis.
    Galluccio F; Matucci-Cerinic M
    Autoimmun Rev; 2011 Mar; 10(5):241-3. PubMed ID: 20863907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic management of acral manifestations of systemic sclerosis].
    Meyer MF; Daigeler A; Lehnhardt M; Steinau HU; Klein HH
    Med Klin (Munich); 2007 Mar; 102(3):209-18. PubMed ID: 17345017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Combined Approach for Digital Necrosis Secondary to Raynaud's Phenomenon.
    Vegas DH; Fabiani MA; Gonzalez-Urquijo M; Bignotti A; Seré I; Salvadores P
    Vasc Endovascular Surg; 2021 Oct; 55(7):766-771. PubMed ID: 33866879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raynaud's phenomenon.
    Devgire V; Hughes M
    Br J Hosp Med (Lond); 2019 Nov; 80(11):658-664. PubMed ID: 31707892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma.
    Moinzadeh P; Nihtyanova SI; Howell K; Ong VH; Denton CP
    Clin Rev Allergy Immunol; 2012 Dec; 43(3):249-55. PubMed ID: 22711501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.
    Ferreli C; Gasparini G; Parodi A; Cozzani E; Rongioletti F; Atzori L
    Clin Rev Allergy Immunol; 2017 Dec; 53(3):306-336. PubMed ID: 28712039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
    Stöcker JK; Schouffoer AA; Spierings J; Schriemer MR; Potjewijd J; de Pundert L; van den Hoogen FHJ; Nijhuis-van der Sanden MWG; Staal JB; Satink T; Vonk MC; van den Ende CHM;
    Rheumatology (Oxford); 2022 Apr; 61(4):1476-1486. PubMed ID: 34260723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma.
    Cappelli L; Wigley FM
    Rheum Dis Clin North Am; 2015 Aug; 41(3):419-38. PubMed ID: 26210127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of digital ulcers in patients with systemic sclerosis].
    Riemekasten G; Hoffmann U; Sunderkötter C; Weiss N; Kuhn A;
    Dtsch Med Wochenschr; 2012 Jan; 137(1-2):34-40. PubMed ID: 22180282
    [No Abstract]   [Full Text] [Related]  

  • 18. Localized and systemic scleroderma.
    Hawk A; English JC
    Semin Cutan Med Surg; 2001 Mar; 20(1):27-37. PubMed ID: 11308134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic sclerosis in adults. Part II: management and therapeutics.
    Jerjen R; Nikpour M; Krieg T; Denton CP; Saracino AM
    J Am Acad Dermatol; 2022 Nov; 87(5):957-978. PubMed ID: 35131401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and Management of Systemic Sclerosis: A Practical Approach.
    Lee JJ; Pope JE
    Drugs; 2016 Feb; 76(2):203-13. PubMed ID: 26659258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.